You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Clinical Evaluation of a Resorbable Vena Cava Filter
SBC: Adient Medical Inc. Topic: NHLBIPROJECT SUMMARYClinical Evaluation of a Resorbable Inferior Vena Cava FilterPulmonary embolismPEis therd leading cause of deathclaiming the lives of at leastAmericans annuallymore than breast cancerAIDSand vehicle fatalities combinedMetallic Inferior Vena CavaIVCfilters have been proven effective in reducing PE to aboutin at risk populationshoweverthey come with a heavy post deployment pricenamely ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Service and Software Solution for the Rigorous Design of Animal Studies
SBC: SERALOGIX, LLC Topic: NIDAThe primary goal of this fast track project is to commercialize a cloud based software suite complemented with on call expert services to guide life science researchersthat may have minimal statistical and experimental designEDknowledgeto rigorously planoptimizejustifymanageand report results for complex animal studiesInadequately planned experimentse glack of randomization blinding and diversityl ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Low Cost Online Real Time Metal Analysis during Pharmaceutical Manufacturing
SBC: UHV TECHNOLOGIES, INC. Topic: NIDAThe purpose of this SBIR Phase II contract is to develop an inexpensive and easy to use instrument that will becapable of measuring low ppm levels at least andlt ppm of a range of metals typically used in the pharmaceuticalindustry The instrument would be co located with the reaction and purification equipment where metal removalis performed and preferably amenable to continuous monitoring ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Lab-on-a-Chip-Based System for Detection and Monitoring of Oral Cancer in Dental Settings
SBC: SensoDX II, LLC Topic: NIDCRDESCRIPTIONprovided by applicantCancers of the oral cavity and pharynx are among the most serious cancerswith approximatelyincidents globallyIn the UStheyear survival rate is approximatelyamong the lowest for all forms of cancerYet when diagnosed in the early stages with confinement to the primary sitethe rate increases dramatically to aboutFurthercancers of the oral cavity are among the most expe ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel MRI Contrast Agent for Detection of Beta Amyloid
SBC: Alzeca Biosciences Topic: NIAProject SummaryAlzheimer s diseaseADis the most common form of dementiaaffecting roughlymillion Americansand is the sixth leading cause of death in the United StatesQuantification of amyloidAplaque burden withF andCbased Positron Emission TomographyPETimaging agentsbased on high affinity Aaggregate binding radionuclides shows promise for identifying individuals with increased risk of progressing t ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Aspirin-PC for Chemoprevention of Colorectal Cancer
SBC: PLx Opco Inc. Topic: NCIABSTRACT Colorectal cancerCRCis the third leading cause of cancer related deaths in the U SBased on numerous epidemiological studies and recent prospective clinical trialsthe use of daily aspirin is associated with a significant reduction in CRC incidencedeaths and metastatic spreadHoweverthe chronic use of this drug is limited due to the side effects of gastrointestinal bleeding ulceration in sus ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Oral Small Molecule STAT Inhibitor to Treat Cachexia in Chronic Kidney Disease
SBC: StemMed, Ltd. Topic: 400DESCRIPTION provided by applicant Chronic kidney disease CKD is a major public health problem in the US with an estimated prevalence of million patients enter hemodialysis or peritoneal dialysis programs yearly A serious complication in of patients with CKD is cachexia or muscle wasting which decreases quality of life and increases morbidity and mortality Unfortunately ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
A Phase I trial combining IV fenretinide and IV safingol to target overproduction
SBC: CERRX, INC. Topic: NCICerRxIncLubbock TXa clinical stage anticancer drug development start up companyrequests critical funding via this SBIR Fast Track Phase I II application to support a highly noveladult Phase I clinical trial of intravenous fenretinidesafingolfor which it licenses both formulation and drug combination IP rightsThis trial will be subcontracted to the academic West Texas basedSouth Plains Oncology Con ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Genotyped and Single Cyst-derived Human ADPKD Cell Platforms for Industry and Academia
SBC: DISCOVERYBIOMED, INC. Topic: 100DiscoveryBioMedIncDBMIncor DBMspecializes in normal and diseased human cell platform engineeringDBM has assembled a consortium of expertswherebycollectivelywe seek Fast Track SBIR funding to establish and offer a Product Line Menu of normal and ADPKD human cell platforms for the academic and industry marketplacesExisting and interested DBM clients will be presented in terms of which options in the ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of high-throughput cardiotoxicity and hepatotoxicity assays with magnetic 3D bioprinting
SBC: CHEMOSEN3D INC Topic: 113PROJECT SUMMARYThe goal of this proposal is to develop assays for cardiotoxicity and hepatotoxicity using magneticD bioprintingBoth cardiotoxicity and hepatotoxicity are critical areas for safety testingand in need of more accurate in vitro screens to prevent costly market withdrawalsHowevercurrent in vitro options are lacking in throughput and representation of native tissue environmentsThis prop ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health